menu

Advances in Angiostatic Treatment for Retinal Disease: Demystifying Novel Therapeutic Targets

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Advances in Angiostatic Treatment for Retinal Disease: Demystifying Novel Therapeutic Targets

close
0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Current challenges in the treatment of neovascular retinal disease include the tremendous burden of treatment and suboptimal response to treatment in many cases. Strides have been made recently toward therapies that deliver increased efficacy vs traditional first-line therapies, a decreased treatment burden, or both. To achieve these ends, next-generation treatment strategies target multiple angiogenic cellular pathways at once. In this activity, experts in retinal disease treatment use custom animations to discuss the mechanisms of action of various novel treatment strategies. The latest clinical trial data for faricimab and OPT-302, two molecules currently in phase 3 clinical trials for the treatment of retinal disease, are also presented.

  • Disclosure of Conflicts of Interest

    Disclosure Policy
    MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.

    Faculty
    David Eichenbaum, MD, is a consultant for Alimera Sciences, Allergan, Apellis Pharmaceuticals, D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., EyePoint Pharmaceuticals, Genentech, Inc, Gyroscope, IVERIC bio, KKR, Kodiak Sciences Inc, Notal Vision, Novartis Pharmaceuticals Corporation, Recens Medical, Inc, and Regeneron Pharmaceuticals, Inc; is on the speakers bureau for Allergan, Bayer Corporation, D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., EyePoint Pharmaceuticals, and Genentech, Inc; is a contracted researcher for Alkahest, Inc, Allergan, AsclepiX, Bayer Corporation, Chengdu Kanghong Pharmaceutical Group Co Ltd, Gemini Therapeutics, Genentech, Inc, Gyroscope, Ionis Pharmaceuticals, Inc, IVERIC bio, Kodiak Sciences Inc, Mylan NV, NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Opthea, and Regeneron Pharmaceuticals, Inc; and has ownership interest in Clearside Biomedical, Inc, and Hemera Biosciences.

    Charles C. Wykoff, MD, PhD, is a consultant for Adverum, Allergan, Apellis Pharmaceuticals, Arctic Vision (Shanghai) Biotechnology Co., Ltd, Arrowhead Pharmaceuticals, Inc, Bausch & Lomb Incorporated, Bayer Corporation, Bionic Vision Technologies, Chengdu Kanghong Pharmaceutical Group Co Ltd, EyePoint Pharmaceuticals, F. Hoffmann-La Roche Ltd, Genentech, Inc, Gyroscope, IVERIC bio, Kato Pharmaceutical Inc, Kodiak Sciences Inc, Merck & Co., Inc, NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Occurx, Ocular Therapeutix, Inc, ONL Therapeutics, Opthea, Oxurion NV, Palatin Technologies, Inc, PolyPhotonix, Recens Medical, Inc, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Takeda Pharmaceuticals USA, Inc, Thea Pharmaceuticals Limited, and Verana Health; and is a contracted researcher for Adverum, Aerie Pharmaceuticals, Inc, Aldeyra Therapeutics, Alimera Sciences, Apellis Pharmaceuticals, Bayer Corporation, Boehringer Ingelheim, Chengdu Kanghong Pharmaceutical Group Co Ltd, Clearside Biomedical, Inc, F. Hoffmann-La Roche Ltd, Gemini Therapeutics, Genentech, Inc, GrayBug, Inc, Gyroscope, Ionis Pharmaceuticals, Inc, IVERIC bio, Kodiak Sciences Inc, Lowy Medical Research Institute, Neurotech Pharmaceuticals, NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Opthea, Outlook Therapeutics, Inc, Oxurion NV, Recens Medical, Inc, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Samchundang Pharm Co, Ltd, Santen Inc, Senju Pharmaceutical Co, Ltd, Taiwan Liposome Company, Ltd, and Xbrane Biopharma AB.

    Peer Reviewer
    This activity was peer reviewed. The peer reviewer has no relevant financial relationships. 

    Planners and Managers
    MedEdicus planners and managers have no relevant commercial relationships to disclose.

  • Target Audience

    This educational activity is intended for retina specialists and other ophthalmologists caring for patients with nAMD or DME.

  • Learning Objectives

    After completing this activity, participants will be better able to:

    • Describe pathophysiologic mechanisms of emerging combination approaches to treating neovascular age-related macular degeneration and diabetic macular edema
    • Review the latest clinical trial data for approved and emerging combination treatments for neovascular age-related macular degeneration and diabetic macular edema
    • Identify patients who would be good candidates for emerging combination treatment for their neovascular age-related macular degeneration or diabetic macular edema
  • Accreditation and Credit Designation Statements

    ReachMD Healthcare ImageMedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Credit Designation
    MedEdicus LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Instructions for Obtaining Credit
    To obtain AMA PRA Category 1 Credit™ for this activity, please view the webcast, consult referenced sources as necessary, and complete the post test and evaluation online. Upon passing with a score of 70% or higher, a certificate will be made available immediately.

    Off-Label Discussion
    This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

  • Provider(s)/Educational Partner(s)

    This continuing medical education activity is provided by MedEdicus LLC.

    ReachMD Healthcare Image

    For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

  • Commercial Support

    This continuing medical education activity is supported through an unrestricted educational grant from Genentech, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Genentech, Inc.

    This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 246

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Current challenges in the treatment of neovascular retinal disease include the tremendous burden of treatment and suboptimal response to treatment in many cases. Strides have been made recently toward therapies that deliver increased efficacy vs traditional first-line therapies, a decreased treatment burden, or both. To achieve these ends, next-generation treatment strategies target multiple angiogenic cellular pathways at once. In this activity, experts in retinal disease treatment use custom animations to discuss the mechanisms of action of various novel treatment strategies. The latest clinical trial data for faricimab and OPT-302, two molecules currently in phase 3 clinical trials for the treatment of retinal disease, are also presented.

  • Disclosure of Conflicts of Interest

    Disclosure Policy
    MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.

    Faculty
    David Eichenbaum, MD, is a consultant for Alimera Sciences, Allergan, Apellis Pharmaceuticals, D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., EyePoint Pharmaceuticals, Genentech, Inc, Gyroscope, IVERIC bio, KKR, Kodiak Sciences Inc, Notal Vision, Novartis Pharmaceuticals Corporation, Recens Medical, Inc, and Regeneron Pharmaceuticals, Inc; is on the speakers bureau for Allergan, Bayer Corporation, D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., EyePoint Pharmaceuticals, and Genentech, Inc; is a contracted researcher for Alkahest, Inc, Allergan, AsclepiX, Bayer Corporation, Chengdu Kanghong Pharmaceutical Group Co Ltd, Gemini Therapeutics, Genentech, Inc, Gyroscope, Ionis Pharmaceuticals, Inc, IVERIC bio, Kodiak Sciences Inc, Mylan NV, NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Opthea, and Regeneron Pharmaceuticals, Inc; and has ownership interest in Clearside Biomedical, Inc, and Hemera Biosciences.

    Charles C. Wykoff, MD, PhD, is a consultant for Adverum, Allergan, Apellis Pharmaceuticals, Arctic Vision (Shanghai) Biotechnology Co., Ltd, Arrowhead Pharmaceuticals, Inc, Bausch & Lomb Incorporated, Bayer Corporation, Bionic Vision Technologies, Chengdu Kanghong Pharmaceutical Group Co Ltd, EyePoint Pharmaceuticals, F. Hoffmann-La Roche Ltd, Genentech, Inc, Gyroscope, IVERIC bio, Kato Pharmaceutical Inc, Kodiak Sciences Inc, Merck & Co., Inc, NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Occurx, Ocular Therapeutix, Inc, ONL Therapeutics, Opthea, Oxurion NV, Palatin Technologies, Inc, PolyPhotonix, Recens Medical, Inc, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Takeda Pharmaceuticals USA, Inc, Thea Pharmaceuticals Limited, and Verana Health; and is a contracted researcher for Adverum, Aerie Pharmaceuticals, Inc, Aldeyra Therapeutics, Alimera Sciences, Apellis Pharmaceuticals, Bayer Corporation, Boehringer Ingelheim, Chengdu Kanghong Pharmaceutical Group Co Ltd, Clearside Biomedical, Inc, F. Hoffmann-La Roche Ltd, Gemini Therapeutics, Genentech, Inc, GrayBug, Inc, Gyroscope, Ionis Pharmaceuticals, Inc, IVERIC bio, Kodiak Sciences Inc, Lowy Medical Research Institute, Neurotech Pharmaceuticals, NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Opthea, Outlook Therapeutics, Inc, Oxurion NV, Recens Medical, Inc, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Samchundang Pharm Co, Ltd, Santen Inc, Senju Pharmaceutical Co, Ltd, Taiwan Liposome Company, Ltd, and Xbrane Biopharma AB.

    Peer Reviewer
    This activity was peer reviewed. The peer reviewer has no relevant financial relationships. 

    Planners and Managers
    MedEdicus planners and managers have no relevant commercial relationships to disclose.

  • Target Audience

    This educational activity is intended for retina specialists and other ophthalmologists caring for patients with nAMD or DME.

  • Learning Objectives

    After completing this activity, participants will be better able to:

    • Describe pathophysiologic mechanisms of emerging combination approaches to treating neovascular age-related macular degeneration and diabetic macular edema
    • Review the latest clinical trial data for approved and emerging combination treatments for neovascular age-related macular degeneration and diabetic macular edema
    • Identify patients who would be good candidates for emerging combination treatment for their neovascular age-related macular degeneration or diabetic macular edema
  • Accreditation and Credit Designation Statements

    ReachMD Healthcare ImageMedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Credit Designation
    MedEdicus LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Instructions for Obtaining Credit
    To obtain AMA PRA Category 1 Credit™ for this activity, please view the webcast, consult referenced sources as necessary, and complete the post test and evaluation online. Upon passing with a score of 70% or higher, a certificate will be made available immediately.

    Off-Label Discussion
    This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

  • Provider(s)/Educational Partner(s)

    This continuing medical education activity is provided by MedEdicus LLC.

    ReachMD Healthcare Image

    For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

  • Commercial Support

    This continuing medical education activity is supported through an unrestricted educational grant from Genentech, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Genentech, Inc.

    This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 246

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule16 Oct 2021